NR3C2 and heart failure: Conventional steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, reduce mortality in patients with heart failure with reduced ejection fraction while also effectively treating resistant hypertension and lowering proteinuria [9–13].